Loading financial data...

Zentalis Pharmaceuticals, Inc. (ZNTL) Financial Statements | Global Financial Data

Zentalis Pharmaceuticals, Inc.

ZNTLSEC EDGAR

Pharmaceutical PreparationsCIK: 1725160

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue from Contract with Customer, Excluding Assessed Tax	$0.00	—	—	—	—
Research and Development Expense	$172.7M	$175.6M	$84.9M	$38.4M	$7.1M
Operating Expenses	$227.3M	$216.5M	$118.8M	$46.8M	$8.7M
Operating Income (Loss)	-$227.3M	-$216.5M	-$118.8M	-$46.8M	-$8.7M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$237.6M	-$166.4M	-$118.1M	-$46.4M	-$8.7M
Income Tax Expense (Benefit)	-$469.0K	-$297.0K	$444.0K	$15.0K	$3.0K
Net Income (Loss) Attributable to Parent	-$236.8M	-$158.7M	-$117.8M	-$45.7M	-$8.3M
Earnings Per Share, Basic	-$4.48	-$3.72	-$4.19	-$2.88

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$551.7M	$539.3M	$454.5M	$365.6M	$87.5M
Assets, Current	$496.7M	$451.9M	$350.8M	$345.1M	$68.9M
Cash and Cash Equivalents, at Carrying Value	$43.1M	$59.7M	$55.0M	$67.2M	$67.2M
Accounts Receivable, after Allowance for Credit Loss, Current	$0.00	—	—	$417.0K	$140.0K
Liabilities	$114.3M	$105.3M	$90.0M	$32.2M	$19.1M
Liabilities, Current	$69.4M	$56.6M	$43.9M	$28.6M	$14.9M
Accounts Payable, Current	$14.9M	$11.2M	$11.6M	$8.7M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$163.8M	-$154.1M	-$86.8M	-$39.1M	-$39.1M
Net Cash Provided by (Used in) Investing Activities	-$114.2M	-$18.1M	-$284.8M	-$352.0K	-$352.0K
Net Cash Provided by (Used in) Financing Activities	$261.0M	$178.5M	$360.4M	$81.8M	$81.8M
Payments to Acquire Property, Plant, and Equipment	$2.5M	$6.1M	$758.0K	$352.0K	$352.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)